Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement
08 4์ 2009 - 4:00AM
Business Wire
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced, in
compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the
independent audit report included in the Company๏ฟฝs Annual Report on
Form 10-K for the fiscal year ended December 31, 2008 contained an
unqualified audit opinion from its independent public accounting
firm, Ernst & Young LLP, which included a ๏ฟฝgoing concern๏ฟฝ
explanatory statement. This disclosure is required under NASDAQ
rules and does not represent any change to the Company๏ฟฝs Annual
Report on Form 10-K for the year ended December 31, 2008 which was
filed on March 31, 2009 with the Securities and Exchange
Commission.
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class cancer
therapeutics.
Avalon (NASDAQ:AVRX)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 4์(4) 2024 ์ผ๋ก 5์(5) 2024
Avalon (NASDAQ:AVRX)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 5์(5) 2023 ์ผ๋ก 5์(5) 2024
Avalon Pharmaceuticals (MM) (๋์ค๋ฅ)์ ์ค์๊ฐ ๋ด์ค: ์ต๊ทผ ๊ธฐ์ฌ 0
More Avalon Pharmaceuticals, Inc. News Articles